Thermosensitive Gelling System for Dermal Drug Delivery of Rutin

Overview

Journal Turk J Pharm Sci

Specialty Pharmacology

Date 2023 May 10

PMID 37161283

Authors

Sefa Gozcu

Kerem Heybet Polat

Affiliations

Soon will be listed here.

Abstract

Objectives: Rutin has been broadly applied for treating several diseases due to its pharmacological activities. However, its low aqueous solubility limits its absorption and bioavailability. This research aims to increase the solubility of rutin using cyclodextrin and to develop a temperature-triggered gelling system for dermal application.

Materials And Methods: The solubility of rutin was increased with sulfobutyl ether-β-cyclodextrin (SBE-β-CD). Rutin- SBE-β-CD inclusion complex was prepared by kneading and freeze dying method. Structural characterization was carried out using differential scanning calorimetry and fourier transform infrared spectroscopy. gel formulations were prepared with pluronic F127 (PF127), a thermosensitive polymer, and chitosan (CH), a natural, biodegradable, and mucoadhesive hydrophilic polymer. gel characteristics such as pH, clarity, gelation temperature, and viscosity were determined.

Results: When the solubility diagrams were examined, it was concluded that SBE-β-CD showed a linear increase, therefore, AL-type diagram was selected. The formulations were produced using different amounts of PF127 and a fixed ratio of CH. Three gels were evaluated for their pH, gelling temperature, and the rheological behaviors, and one formulation was selected. It was observed that the formulations had a pH between 6-6.1, and their gelation temperature decreased with increasing PF127 that was between 20°C to 34°C. For the selected formulation (formulation E3), 0.5% rutin and rutin/SBE-β-CD were transferred to the gelling system. Because of release studies, it was observed that the release of the rutin/SBE-β-CD inclusion complex containing NZ formulation showed a higher burst effect than the others and the release continued for 6 hours.

Conclusion: The results indicated that the combination of PF127 and CH can be a hopeful gelling vehicle for dermal delivery of rutin and rutin/SBE-β-CD.

Citing Articles

Rutin/Sulfobutylether-β-Cyclodextrin as a Promising Therapeutic Formulation for Ocular Infection.

De Gaetano F, Pastorello M, Pistara V, Rescifina A, Margani F, Barbera V Pharmaceutics. 2024; 16(2).

PMID: 38399286 PMC: 10892075. DOI: 10.3390/pharmaceutics16020233.

References

Edsman K, Carlfors J, Petersson R . Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci. 1998; 6(2):105-12. DOI: 10.1016/s0928-0987(97)00075-4. View

El-Kamel A . In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm. 2002; 241(1):47-55. DOI: 10.1016/s0378-5173(02)00234-x. View

Chat O, Najar M, Mir M, Rather G, Dar A . Effects of surfactant micelles on solubilization and DPPH radical scavenging activity of Rutin. J Colloid Interface Sci. 2011; 355(1):140-9. DOI: 10.1016/j.jcis.2010.11.044. View

Aytekin E, Ozturk N, Vural I, Polat H, Cakmak H, Calis S . Design of ocular drug delivery platforms and in vitro - in vivo evaluation of riboflavin to the cornea by non-interventional (epi-on) technique for keratoconus treatment. J Control Release. 2020; 324:238-249. DOI: 10.1016/j.jconrel.2020.05.017. View

Covre J, Cristovam P, Loureiro R, Hazarbassanov R, Campos M, Sato E . The effects of riboflavin and ultraviolet light on keratocytes cultured in vitro. Arq Bras Oftalmol. 2016; 79(3):180-5. DOI: 10.5935/0004-2749.20160052. View

Nijveldt R, van Nood E, van Hoorn D, Boelens P, van Norren K, Van Leeuwen P . Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr. 2001; 74(4):418-25. DOI: 10.1093/ajcn/74.4.418. View

Ribeiro A, Figueiras A, Santos D, Veiga F . Preparation and solid-state characterization of inclusion complexes formed between miconazole and methyl-beta-cyclodextrin. AAPS PharmSciTech. 2008; 9(4):1102-9. PMC: 2628269. DOI: 10.1208/s12249-008-9143-8. View

Verma A, Tiwari A, Saraf S, Panda P, Jain A, Jain S . Emerging potential of niosomes in ocular delivery. Expert Opin Drug Deliv. 2020; 18(1):55-71. DOI: 10.1080/17425247.2020.1822322. View

Loftsson T, Brewster M . Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010; 62(11):1607-21. DOI: 10.1111/j.2042-7158.2010.01030.x. View

10.

Liu Z, Li J, Nie S, Liu H, Ding P, Pan W . Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm. 2006; 315(1-2):12-7. DOI: 10.1016/j.ijpharm.2006.01.029. View

11.

Dumortier G, Grossiord J, Agnely F, Chaumeil J . A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006; 23(12):2709-28. DOI: 10.1007/s11095-006-9104-4. View

12.

Aiassa V, Zoppi A, Becerra M, Albesa I, Longhi M . Enhanced inhibition of bacterial biofilm formation and reduced leukocyte toxicity by chloramphenicol:β-cyclodextrin:N-acetylcysteine complex. Carbohydr Polym. 2016; 152:672-678. DOI: 10.1016/j.carbpol.2016.07.013. View

13.

Polat H, Kurt N, Aytekin E, Akdag Cayli Y, Bozdag Pehlivan S, Calis S . Design of Besifloxacin HCl-Loaded Nanostructured Lipid Carriers: and Evaluation. J Ocul Pharmacol Ther. 2022; 38(6):412-423. DOI: 10.1089/jop.2022.0008. View

14.

Pawar P, Kashyap H, Malhotra S, Sindhu R . Hp-β-CD-voriconazole in situ gelling system for ocular drug delivery: in vitro, stability, and antifungal activities assessment. Biomed Res Int. 2013; 2013:341218. PMC: 3665163. DOI: 10.1155/2013/341218. View

15.

Williams H, Trevaskis N, Charman S, Shanker R, Charman W, Pouton C . Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013; 65(1):315-499. DOI: 10.1124/pr.112.005660. View

16.

Jithan A, Krishna Mohan C, Vimaladevi M . Development and evaluation of a chloramphenicol hypertonic ophthalmic solution. Indian J Pharm Sci. 2010; 70(1):66-70. PMC: 2852064. DOI: 10.4103/0250-474X.40334. View

17.

Almeida H, Amaral M, Lobao P, Sousa Lobo J . In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov Today. 2013; 19(4):400-12. DOI: 10.1016/j.drudis.2013.10.001. View

18.

Almeida J, Lima F, Da Ros S, Bulhoes L, de Carvalho L, Beck R . Nanostructured Systems Containing Rutin: In Vitro Antioxidant Activity and Photostability Studies. Nanoscale Res Lett. 2010; 5(10):1603-10. PMC: 2956028. DOI: 10.1007/s11671-010-9683-1. View

19.

Srividya B, Cardoza R, Amin P . Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release. 2001; 73(2-3):205-11. DOI: 10.1016/s0168-3659(01)00279-6. View

20.

Muxika A, Etxabide A, Uranga J, Guerrero P, de la Caba K . Chitosan as a bioactive polymer: Processing, properties and applications. Int J Biol Macromol. 2017; 105(Pt 2):1358-1368. DOI: 10.1016/j.ijbiomac.2017.07.087. View